All Articles: News
A successful first-in-human clinical study of YCT-529, a hormone-free birth control pill for men developed by Dr. Gunda Georg of the College of Pharmacy and YourChoice Therapeutics, demonstrated its safety.
Findings open new opportunities to seek BioB inhibitors to treat infections with M. tuberculosis and other pathogens.
Initial preclinical studies showed YCT-529 was 99% effective and 100% reversible with no side effects.
Findings can be used to decrease the negative impact on drug discovery of compounds that cause non-specific cell injury.
Research continues in collaboration with researchers at Harvard Medical School